Your shopping cart is currently empty

TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 100 mg | Inquiry | Inquiry | Inquiry | |
| 500 mg | Inquiry | Inquiry | Inquiry |
| Description | TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. |
| Targets&IC50 | GLP1 receptor:(EC50)5 nM |
| In vitro | TT-OAD2, at concentrations ranging from 0 to 10 μM, suppresses GLP-1- and oxyntomodulin-induced responses—including cAMP, calcium, pERK1/2, and β-arrestin—in a dose-dependent manner within HEK293A cells. |
| In vivo | TT-OAD2 ?treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice. |
| Molecular Weight | 856.83 |
| Formula | C50H47Cl2N3O6 |
| Cas No. | 1246826-07-2 |
| Smiles | [C@@H](CC)(N1[C@H](C(N[C@@H](CC2=CC=C(C=C2)C=3C(C)=C(C)N=CC3)C(O)=O)=O)CC=4C(C1)=CC5=C(C4)OC[C@@](O5)(C6=CC=C(OCC7=CC(Cl)=C(Cl)C=C7)C=C6)[H])C8=CC=CC=C8 |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.